Forma Therapeutics Holdings Inc (FMTX) Stock
FMTX is no longer traded. Forma Therapeutics Holdings was delisted from the Nasdaq in October 2022.
Prices on this page are historical; the last trade was October 13, 2022 at $20.01.
Forma Therapeutics Holdings stock price history
FMTX final trading statistics
- Final close
- $20.01
- Final trading day
- Oct 13, 2022
- Market cap at delisting
- $957.69M
- Shares outstanding
- 47.86M
- Final 52-week range
- $4.95 – $20.68
- Avg. volume (final 3 mo.)
- 1,467,904
- All-time high (split-adj.)
- $51.08 · Dec 2020
- All-time low (split-adj.)
- $5.10 · Jun 2022
- Return since IPO
- -48.7%
- Beta
- -0.95
- Book value / share
- $8.67
- Price / book
- 2.31
Forma Therapeutics Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$173.0M | -$3.65 |
| FY2020 | $0.00 | -$70.4M | -$5.51 |
| FY2019 | $100.56M | -$34.8M | — |
| FY2018 | $164.09M | $5.3M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Forma Therapeutics Holdings Inc
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
Forma Therapeutics Holdings stock FAQ
What happened to Forma Therapeutics Holdings stock?
Forma Therapeutics Holdings stock was delisted from the Nasdaq. Its final close was $20.01 on October 13, 2022.
Is FMTX stock still trading?
No. FMTX was delisted from the Nasdaq in October 2022 and no longer trades on a U.S. exchange.
What was the last price of FMTX stock?
FMTX closed at $20.01 on its final trading day, October 13, 2022, for a market value of about $957.69M.
What were Forma Therapeutics Holdings's revenue and earnings in its last full fiscal year?
Forma Therapeutics Holdings reported revenue of $0.00 and net income of -$173.0M in fiscal 2021, its last full year as a public company.
When did Forma Therapeutics Holdings go public?
Forma Therapeutics Holdings Inc stock began trading on June 19, 2020.